BIL 06v

Drug Profile

BIL 06v

Alternative Names: BIL-06v

Latest Information Update: 07 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biosceptre International; Peptech UK
  • Developer Biosceptre International
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Purinergic P2X7 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Dec 2017 Biosceptre plans a phase I trial for of BIL 06v for Cancer in Australia in 2018 (ACTRN12618000838213)
  • 31 May 2016 Preclinical trials in Cancer in United Kingdom (Parenteral) before May 2016
  • 31 May 2016 Biosceptre plans a phase I trial of BIL 06v for Solid tumours in the United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top